Development of a novel nonradiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreen®technology

Journal of Biomolecular Screening

Volumn 15, Issue 9, 2010, Pages 1099-1106

  Cassel, Joel A ^a   Blass, Benjamin E ^b   Reitz, Allen B ^a   Pawlyk, Aaron C ^a  

^a Pennsylvania Biotechnology Center   (United States)

^b Pennsylvania Drug Discovery Institute   (United States)

Author keywords

AlphaScreen; ALS; cystic fibrosis; TAR DNA; TDP 43

Indexed keywords

NUCLEIC ACID; NUCLEIC ACID BINDING PROTEIN; OLIGONUCLEOTIDE; SINGLE STRANDED DNA; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DISSOCIATION; FRONTOTEMPORAL DEMENTIA; HALF LIFE TIME; HIGH THROUGHPUT SCREENING; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; RADIOMETRY; TANDEM REPEAT; TECHNOLOGY;

BIOTINYLATION; DNA; DNA-BINDING PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV LONG TERMINAL REPEAT; HUMANS; KINETICS; PROTEIN BINDING; RADIOMETRY; REPETITIVE SEQUENCES, NUCLEIC ACID; RNA; SMALL MOLECULE LIBRARIES; TEMPERATURE;

EID: 78650083095     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110382778     Document Type: Article

References (23)

1. Buratti E., Baralle FE: Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 2008 ; 13: 867-878.
2. Ou SH, Wu F., Harrich D., Garcia-Martinez LF, Gaynor RB: Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995 ; 69: 3584-3596.
3. Buratti E., Brindisi A., Pagani F., Baralle FE: Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet 2004 ; 74: 1322-1325.
4. Buratti E., Dork T., Zuccato E., Pagani F., Romano M., Baralle FE: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001 ; 20: 1774-1784.
5. Ayala YM, Pagani F., Baralle FE: TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett 2006 ; 580: 1339-1344.
6. Ayala YM, Misteli T., Baralle FE: TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 2008 ; 105: 3785-3789.
7. Kuo PH, Doudeva LG, Wang YT, Shen CK, Yuan HS: Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res 2009 ; 37: 1799-1808.
8. Buratti E., Baralle FE: Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001 ; 276: 36337-36343.
9. Pawlyk AC, CJ, Reitz AB: Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis. Curr Pharm Des 2010 ; 16: 2053-2073.
10. Buratti E., Baralle FE: The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 2009 ; 66: 1-34.
11. Geser F., Martinez-Lage M., Kwong LK, Lee VM, Trojanowski JQ: Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol 2009 ; 256: 1205-1214.
12. Strong MJ: The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008 ; 9: 323-338.
13. Kwong LK, Neumann M., Sampathu DM, Lee VM, Trojanowski JQ: TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol 2007 ; 114: 63-70.
14. Banks GT, Kuta A., Isaacs AM, Fisher EM: TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mamm Genome 2008 ; 19: 299-305.
15. Lagier-Tourenne C., Cleveland DW: Rethinking ALS: the FUS about TDP-43. Cell 2009 ; 136: 1001-1004.
16. Liscic RM, Grinberg LT, Zidar J., Gitcho MA, Cairns NJ: ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 2008 ; 15: 772-780.
17. Pesiridis GS, Lee VM, Trojanowski JQ: Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 2009 ; 18: R156 - R162.
18. Barmada SJ, Skibinski G., Korb E., Rao EJ, Wu JY, Finkbeiner S.: Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 2010 ; 30: 639-649.
19. Feiguin F., Godena VK, Romano G., D'Ambrogio A., Klima R., Baralle FE: Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett 2009 ; 583: 1586-1592.
20. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
21. Limbird L.: Cell Surface Receptors: A Short Course on Theory and Methods. Norwell, MA: Kluwer Academic, 1996.
22. Ayala YM, Pantano S., D'Ambrogio A., Buratti E., Brindisi A., Marchetti C., et al. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol 2005 ; 348: 575-588.
23. Sephton CF, Good SK, Atkin S., Dewey CM, Mayer P. III, Herz J., et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem; 2010 ; 285: 6826-6834.